Donavan Cheng

Donavan Cheng is an accomplished professional with extensive experience in bioinformatics, science, and technology leadership within the genetics and oncology sectors. As Chief Science and Technology Officer at Ambry Genetics from May 2022 to February 2025, Donavan led a 200-person organization and managed the product and technology roadmap. Prior roles include VP of Informatics at Ambry Genetics, Sr. Director of Bioinformatics at Guardant Health, where Donavan oversaw critical assay development efforts, and Director of Product Management at Illumina, focusing on complex genetic diseases. Donavan's background also includes significant contributions at Memorial Sloan-Kettering Cancer Center and Hoffmann-La Roche, where expertise in machine learning and bioinformatics was applied to various medical research projects. Donavan holds a PhD in Biomedical Engineering from The Johns Hopkins University and a BASc in Engineering Science/Biomedical Engineering from the University of Toronto.